e.l.f. Beauty ELF 深 沪
已收盘 08-01 16:00:00 美东时间
116.42
-4.770
-3.94%
华盛通- 最 高119.53
- 今 开118.60
- 成交量 137.27万股
- 最 低 115.07
- 昨 收 121.19
- 总市值 65.58亿
- 52周最高 172.49
- 市盈率 静 60.60
- 换手率 2.44%
- 52周最低 49.40
- 委 比 97.15%
- 总股本 5632.84万
- 历史最高 221.8299
- 量 比 1.06
- 振 幅 3.68%
- 历史最低 6.705
- 每 手 1
- 风险率 30.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多e.l.f. Beauty Stock Outlook: Post-Rally Uncertainty Sets In
e.l.f. Beauty has completed its Adhishthana Himalayan formation and now sits in a transitional phase. Here's a breakdown of its structure
08-01 21:02
“特朗普关税输家”指数跌0.47%
周三（7月30日），“特朗普关税输家”指数跌0.47%，报104.71点。成分股中，北极星收跌8.29%，纽威、卡特、道指成分股3M跌3.87%-3.41%，耐...
07-31 05:29
美股大行评级 | 潜在涨幅102.43%！Mobileye Global获Canaccord Genuity升目标价至30美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Mobileye Global"买入"评级，目标价从25美元升至30美元；巴克莱：维持TechnipFMC"超配"评级，目标价从45美元升至51美元
07-28 09:33
JP Morgan Maintains Overweight on e.l.f. Beauty, Raises Price Target to $132
JP Morgan analyst Andrea Teixeira maintains e.l.f. Beauty (NYSE:ELF) with a Overweight and raises the price target from $123 to $132.
07-26 05:55
Assessing e.l.f. Beauty: Insights From 22 Financial Analysts
22 analysts have expressed a variety of opinions on e.l.f. Beauty (NYSE:ELF) ov...
07-17 22:02
UBS Maintains Neutral on e.l.f. Beauty, Raises Price Target to $120
UBS analyst Peter Grom maintains e.l.f. Beauty (NYSE:ELF) with a Neutral and raises the price target from $95 to $120.
07-17 21:17
Analysts Offer Insights on Consumer Cyclical Companies: e.l.f. Beauty (ELF) and Gambling.com (GAMB)
There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analy...
07-16 18:51
美股大行评级 | 潜在涨幅107.37%！花旗上调ProKidney目标价至9美元，维持"买入"评级
今日重点评级关注：花旗：维持ProKidney Corp. - Class A Ordinary Shares"买入"评级，目标价从6美元升至9美元；Canaccord Genuity：维持e.l.f. Beauty"买入"评级，目标价从114美元升至150美元
07-10 09:55
Canaccord Genuity Maintains Buy on e.l.f. Beauty, Raises Price Target to $150
Canaccord Genuity analyst Susan Anderson maintains e.l.f. Beauty (NYSE:ELF) with a Buy and raises the price target from $114 to $150.
07-10 00:21
Altimmune Enrols First Patient In RESTORE Phase 2 Trial Evaluating Efficacy And Safety Of Pemvidutide In Subjects With Alcohol-Associated Liver Disease
Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in
07-09 19:31
